NAD+ vs NR vs NMN: What the Difference Is, What the Human Trials Show, and Which One You Actually Need

General information, checked against the human trials cited below. Not medical advice.

Three names dominate the longevity aisle: NAD+, NR and NMN. They are related molecules on the same metabolic pathway, sold at very different prices with very different claims. If you are comparing NAD vs NR vs NMN because you have already decided to try one, this page is written to get you to the right answer quickly — including the answer “not the one we sell.” We make an NR-based formula and no NMN product. We will tell you where NMN might suit you better anyway.

How we compared them

We limited ourselves to human data. Every efficacy claim below comes from a randomised or controlled human trial with a PubMed identifier you can open. Mouse data is mentioned once, to explain why the marketing exists. We compared the three compounds on five criteria: what they are, whether oral dosing raises blood NAD+ in people, what clinical outcomes have actually been measured, safety record, and regulatory status in the United States as of September 2026. We then checked our own label against the same criteria.

The pathway in one paragraph

NAD+ — nicotinamide adenine dinucleotide — is the coenzyme every cell uses to move electrons in energy metabolism and as a substrate for the repair enzymes (sirtuins, PARPs) that consume it. Cells rebuild it constantly through the salvage pathway: nicotinamide riboside (NR) is phosphorylated by NRK enzymes into nicotinamide mononucleotide (NMN), and NMN is converted by NMNAT enzymes into NAD+. So the order is NR → NMN → NAD+. That is the entire basis of the “NMN is one step closer” argument, and also of the counter-argument that NMN is largely converted back to NR at the cell surface before it gets in. Both camps have published; the honest state of play is that oral NR and oral NMN both raise blood NAD+ in humans, and the upstream mechanics are still being argued in the primary literature.

NAD+ itself: the strongest-looking word, the weakest human data

Swallowing NAD+ is intuitive and largely unsupported. NAD+ is a large, charged molecule, and there is no published human pharmacokinetic trial showing that oral NAD+ raises blood NAD+ the way the precursors do. Intravenous NAD+ exists as a clinic offering, with its own small literature and its own side-effect profile, but that is not what is in a capsule.

On our label: our NAD+ formula contains 400 mg of NAD (β-nicotinamide adenine dinucleotide) per serving. We assay it — one released lot (2410366) tested at 462.58 mg by HPLC against a 400–500 mg specification — so the number is real. But the claim it can honestly support is limited, and the human absorption evidence in the product sits with the 250 mg of nicotinamide riboside chloride beside it. We would rather say that here than let the front of the jar imply otherwise.

NR: the longest human record

Nicotinamide riboside is a form of vitamin B3. It has the most human trials of the three, largely because one patented ingredient (Niagen®) funded them.

• It raises blood NAD+ dose-dependently. In the first human pharmacokinetic study, a single oral dose raised blood NAD+ at 100, 300 and 1,000 mg (Trammell et al., 2016, PMID 27721479). An eight-week randomised, placebo-controlled trial in 140 overweight adults then showed the rise holds: whole-blood NAD+ up 22 %, 51 % and 142 % at the same three doses, reached within two weeks and maintained, with adverse events no different from placebo (Conze et al., 2019, PMID 31278280).
• Tissue responds. In aged men given 1 g a day for 21 days, skeletal-muscle NAD+ metabolites rose and the muscle transcriptome shifted toward an anti-inflammatory signature (Elhassan et al., 2019, PMID 31412242).
• Hard outcomes mostly do not. Forty obese, insulin-resistant men took 2,000 mg a day for twelve weeks and were assessed with the reference clamp method: insulin sensitivity, glucose production, energy expenditure and body composition were all unchanged (Dollerup et al., 2018, PMID 29992272). In healthy middle-aged and older adults, six weeks of 1,000 mg was well tolerated and raised NAD+, but the authors concluded that blood pressure and arterial stiffness should be tested in future — not that a benefit was shown (Martens et al., 2018, PMID 29599478).

Regulatory status: NR has been the subject of a successful New Dietary Ingredient notification and is GRAS-affirmed for the branded ingredient. Uncontroversial.

NMN: a shorter record, one striking result, and a regulatory rollercoaster

Nicotinamide mononucleotide has fewer human trials than NR, but they are not trivial.

• Safe and raises NAD+. A single-dose study of up to 500 mg in healthy Japanese men found no safety signal and measurable metabolite changes (Irie et al., 2020, PMID 31685720). Chronic dosing at 250 mg a day for twelve weeks raised blood NAD+ in older men (Igarashi et al., 2022, PMID 35927255).
• One functional result NR has not matched. A ten-week randomised, placebo-controlled trial of 250 mg NMN a day in 25 postmenopausal women with prediabetes reported improved skeletal-muscle insulin sensitivity by the clamp method (Yoshino et al., 2021, PMID 33888596). It is small, it is one population, and it measured a mechanism rather than a disease outcome — but it is the closest thing this whole category has to a clinical effect, and it belongs to NMN, not NR.
• Regulatory status: in November 2022 the FDA stated NMN was excluded from the dietary-supplement definition because it had been investigated as a drug first. In September 2025 the agency reversed that position, and NMN is again lawfully marketable as a supplement subject to standard NDI rules (AboutNAD; Superpower). Practical consequence: the NMN market spent nearly three years in a grey zone, and quality varies more between NMN brands than between NR brands. Ask for a lot-specific certificate of analysis with an identity test, not just potency.

Side by side

Which one, and for whom

Choose NR if you want the longest human safety record, the clearest dose-response data, and an ingredient whose supply chain was never in regulatory limbo. The sensible reference dose is 300 mg a day — the arm that produced a 51 % rise in blood NAD+ over eight weeks. Our formula carries 250 mg of NR chloride, which is below that arm; we print the comparison rather than round it away.

Choose NMN if the Yoshino result matters to you — specifically, if you are a postmenopausal woman with prediabetes, or you and your doctor are interested in the muscle insulin-sensitivity signal — and you can find a brand that publishes identity and potency testing by lot. We do not make an NMN product. If that describes you, NMN is a reasonable choice and we would rather say so than sell you the wrong molecule.

Choose oral NAD+ alone if — honestly, we cannot construct that case from human data. If a product is NAD+ only, the front label is doing the work the evidence cannot.

Choose none of them if you are under about 35 and sleeping six hours. The human decline in NAD+ was observed in middle-aged and older tissue; at 32, sleep, protein and resistance training will out-earn any precursor. And none of the three treats disease: fatigue with weight change, palpitations or heavy periods is a doctor’s question before it is a supplement’s.

What to check on any NAD+ product label

• The precursor on its own line with a milligram figure. “1,400 mg NAD+ complex” is a total — ours included. What you want is the NR or NMN number.
• Serving size before comparing prices; two or three capsules per serving is common.
• No proprietary blend. A blend makes the trial comparison impossible.
• Lot-specific certificate of analysis covering identity and potency, not a seal on the jar. For NMN, identity testing matters more because of the market’s recent history.
• Allergens. Ours contains fish collagen (cod and/or tilapia) — unsuitable for fish allergy and for vegetarians. Read the line.

For the full method, see How to Read a Supplement Label.

Safety, for all three

Well tolerated in trials of healthy adults is not the same as safe alongside your prescription. Talk to a clinician first if you take regular medication. Not for pregnancy, trying to conceive, breastfeeding, or under-18s — none of the trials included those groups. Anyone with a current or past cancer diagnosis should ask their oncologist: NAD+ is used by dividing cells of every kind, and the long-term effect of raising it in that setting has not been established in humans.

Frequently asked questions

Is NMN better than NR?

No head-to-head human trial has established that either produces a clinical outcome the other does not. NR has the larger safety and dose-response dataset; NMN has one small trial showing a functional metabolic effect. Anyone ranking them with confidence is filling a data gap with an opinion.

Can I take NR and NMN together?

There is no human trial of the combination. Both funnel into the same pathway, so stacking them mostly stacks cost. Pick one at a studied dose.

Does oral NAD+ get into cells?

Not on the published human evidence. The absorption data belong to the precursors.

Is NMN legal in the US in 2026?

Yes. The FDA reversed its 2022 exclusion in September 2025. Quality still varies by brand; ask for lot testing.

How long before I notice anything?

Blood NAD+ moves within two weeks in the trials. Anything you might actually feel is downstream and slower — give it eight to twelve weeks and judge it on something observable, like recovery between training sessions, not on “cellular energy”.

Why does 4Well include NAD+ itself if the evidence sits with NR?

Because the formula was built to carry both, and we assay the NAD content rather than pretend it is not there. The claim we make is attached to the NR. If you only want the precursor, a single-ingredient NR product is a legitimate alternative, and we say that on the product page.

Conclusion

NAD+, NR and NMN are three points on one pathway, not three tiers of quality. Oral NAD+ has the weakest human evidence; NR has the longest safety and dose-response record; NMN has fewer trials but the one functional result the category can point to, and it is legal again in the US as of late 2025. Choose by the trial that matches you, buy at the studied dose, and check the certificate by lot. Our NAD+ formula is an NR-based product with the doses printed and compared to the trials above — and if NMN fits you better, we have said where to look.

Related: NAD+ Supplements: What Raises It, What It Changes, and What It Does Not · Resveratrol 1800 mg · NAD+ Supplement Facts panel

References

1. Trammell SA et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016;7:12948. PMID 27721479
2. Conze D et al. Sci Rep 2019;9:9772. PMID 31278280
3. Elhassan YS et al. Cell Rep 2019;28(7):1717–1728. PMID 31412242
4. Dollerup OL et al. Am J Clin Nutr 2018;108(2):343–353. PMID 29992272
5. Martens CR et al. Nat Commun 2018;9:1286. PMID 29599478
6. Irie J et al. Endocr J 2020;67(2):153–160. PMID 31685720
7. Igarashi M et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD levels and alters muscle function in healthy older men. NPJ Aging 2022. PMID 35927255
8. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021;372(6547):1224–1229. PMID 33888596
9. FDA NMN reversal, September 2025 — AboutNAD summary; Superpower guide

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.